— Aethlon Medical (NASDAQ: AEMD) reported third quarter 2020 net loss attributable to company of $820,000 or $0.28 per share vs. a loss of $2.1 million $1.67 per share in the prior-year quarter.
— Government contract revenue was $413,458 for the three months ended December 31, 2019.
— Operating expenses were $1.29 million compared to $1.96 million in the three months ended December 31, 2018.
— Aethlon announced that SEC had temporarily suspended trading of the company stock for a period of ten days.
— Aethlon clarified that its proprietary blood filtration cartridge Hemopurifier, which is in the development stage, would not be an initial front line treatment for the 2019-nCoV virus.